$33.35
+1.89
(+6.03%)
As of Oct 20, 2026, 4:10 PM EDT
Price history
Doximity (DOCS) is trading up at $33.35 (+6.03%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.
IPO: June 24, 2021 · $26.00 offering · NYSE · View IPO details →
Doximity revenue & net income history (FY2020–FY2026)
RevenueNet incomeNet margin (right axis, %)
| FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $116.4M | $206.9M | $343.5M | $419.1M | $475.4M | $570.4M | $644.9M |
| Growth (year over year) | — | +77.8% | +66.0% | +22.0% | +13.5% | +20.0% | +13.1% |
| Gross profit | $101.5M | $175.7M | $303.8M | $365.6M | $424.8M | $514.5M | $574.5M |
| Gross margin | 87.2% | 84.9% | 88.4% | 87.2% | 89.3% | 90.2% | 89.1% |
| Operating income | $22.2M | $53.3M | $113.5M | $125.1M | $163.9M | $227.8M | $214.9M |
| Operating margin | 19.0% | 25.8% | 33.0% | 29.9% | 34.5% | 39.9% | 33.3% |
| Net income | $29.7M | $50.2M | $154.8M | $112.8M | $147.6M | $223.2M | $196.1M |
| Net margin | 25.5% | 24.3% | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% |
| EPS (diluted) | $0.13 | $0.23 | $0.70 | $0.53 | $0.72 | $1.11 | $0.98 |
| Balance sheet | |||||||
| Cash and equivalents | $48.4M | $66.4M | $112.8M | $158.0M | $96.8M | $209.6M | $219.2M |
| Total assets | — | $251.7M | $991.4M | $1.14B | $1.08B | $1.26B | $1.12B |
| Total liabilities | — | $103.5M | $112.8M | $170.8M | $178.0M | $181.7M | $172.8M |
| Shareholders' equity | $1.14M | $66.7M | $878.6M | $966.1M | $901.4M | $1.08B | $950.8M |
| Cash flow | |||||||
| Operating cash flow | $26.2M | $83.0M | $126.6M | $179.6M | $184.1M | $273.3M | $326.5M |
| Capital expenditure | $285.0K | $245.0K | $1.91M | $1.70M | $147.0K | $0 | $0 |
| Free cash flow | $25.9M | $82.7M | $124.7M | $177.9M | $183.9M | $273.3M | $326.5M |
| Share buybacks | $0 | $2.02M | $2.70M | $85.3M | $280.7M | $120.3M | $431.7M |
RevenueNet incomeNet margin (right axis, %)
| Q2 FY25Sep 2024 | Q3 FY25Dec 2024 | Q4 FY25†Mar 2025 | Q1 FY26Jun 2025 | Q2 FY26Sep 2025 | Q3 FY26Dec 2025 | Q4 FY26†Mar 2026 | Q1 FY27Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $136.8M | $168.6M | $138.3M | $145.9M | $168.5M | $185.1M | $145.4M | $156.6M |
| Growth (year over year) | +20.4% | +24.6% | +17.1% | +15.2% | +23.2% | +9.8% | +5.1% | +7.3% |
| Gross profit | $123.2M | $154.4M | $123.8M | $130.1M | $152.1M | $166.4M | $126.0M | $132.9M |
| Gross margin | 90.0% | 91.6% | 89.5% | 89.2% | 90.3% | 89.9% | 86.7% | 84.9% |
| Operating income | $53.1M | $79.9M | $48.7M | $54.5M | $63.7M | $71.9M | $24.8M | $33.6M |
| Operating margin | 38.8% | 47.4% | 35.2% | 37.4% | 37.8% | 38.9% | 17.1% | 21.5% |
| Net income | $44.2M | $75.2M | $62.5M | $53.3M | $62.1M | $61.6M | $19.1M | $24.3M |
| Net margin | 32.3% | 44.6% | 45.2% | 36.5% | 36.8% | 33.3% | 13.1% | 15.5% |
| EPS (diluted) | $0.22 | $0.37 | $0.31 | $0.27 | $0.31 | $0.31 | $0.09 | $0.13 |
| Balance sheet | ||||||||
| Cash and equivalents | $184.2M | $165.3M | $209.6M | $137.3M | $169.2M | $64.8M | $219.2M | $273.6M |
| Total assets | $1.12B | $1.17B | $1.26B | $1.20B | $1.26B | $1.16B | $1.12B | $1.08B |
| Total liabilities | $157.3M | $141.0M | $181.7M | $178.9M | $161.6M | $177.7M | $172.8M | $167.8M |
| Shareholders' equity | $961.2M | $1.03B | $1.08B | $1.03B | $1.10B | $979.3M | $950.8M | $916.1M |
| Cash flow | ||||||||
| Operating cash flow | $68.3M | $65.2M | $98.5M | $62.1M | $93.9M | $60.9M | $109.5M | $42.0M |
| Capital expenditure | $0 | $0 | $0 | $0 | — | — | — | $62.0K |
| Free cash flow | $68.3M | $65.2M | $98.5M | $62.1M | — | — | — | $41.9M |
| Share buybacks | $23.0M | $19.3M | $26.8M | $122.4M | $21.9M | $196.9M | $90.5M | $91.6M |
From Doximity's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Doximity
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
- Headquarters
- San Francisco, California From SEC filings, Oct 2026
Recent News (20)
-
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Oct. 19, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Doximity, Inc. ("Dox…
-
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit NEW YORK, Oct. 17, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 202…
-
Doximity CAO Sitaram sells $80,166 of company stock
Doximity CAO Sitaram sells $80,166 of company stock
-
-
-
DOCS Shareholder Alert: Doximity, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt Doximity co-founder and former Chief Strategy Officer Nate Gross is named as a defendant in a securities class action alleging the Company assured investors it could "gain share" while older advertisi…
-
DOCS Stockholders Have Rights - If you Lost Money Investing in Doximity, Inc. Contact Robbins LLP for Information About Recovering Your Losses SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired D…
-
Doximity, Inc. (DOCS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Oct. 14, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action law…
-
-
-
-
-
-
-
Doximity director Kira Wampler sells $57,820 in stock
Doximity director Kira Wampler sells $57,820 in stock
-
-
-
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Doximity, Inc. (NYSE: DOCS) between August 8, 2024 and May 13, 2026…
-
-
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International